Since ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) target different pathways, it’s not entirely surprising that these checkpoint inhibitors are associated with different types of patient responses. For example, anti-CTLA-4 treatment mediates extremely durable responses, while anti-PD-1 treatment can promote higher initial response rates. To figure out what is responsible for this, Dr. Mok is determining how each of these treatments affect memory T cell development, which allows the immune system to provide long-term, durable protection against cancer. Once it is known how each of these treatments influences potential long-term anti-tumor activity, then steps can be taken to amplify these effects and improve patient outcomes.
Projects and Grants
Effects of anti-CTLA-4 and anti-PD-1 on memory T-cell differentiation
The University of Texas MD Anderson Cancer Center | All Cancers | 2016 | James P. Allison, Ph.D.
Let's spread the word about Immunotherapy! Click to share this page with your community.